Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hetero Gets CDSCO Panel Nod to Study Tedizolid Phosphate for Bacterial Skin Infections
Details : Tedizolid phosphate is an oxazolidinone-class antibacterial drug indicated in adult patients for the treatment of acute bacterial skin and skin structure infections.
Product Name : Tedizolid Phosphate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 16, 2024
Lead Product(s) : Tedizolid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hetero’s ‘NIRMACOM’ (nirmatrelvir), a generic version of Pfizer’s COVID-19 oral antiviral drug ‘PAXLOVID’ is co-packaged with ritonavir tablets. The combi pack, launched by Hetero as NIRMACOM, will contain nirmatrelvir 150 mg (2 tablets) and ...
Product Name : Nirmacom
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer's "Game-Changing" COVID-19 pill, Paxlovid, Gets India’s DCGI Nod
Details : India's drug regulator approved antiviral medication Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for restricted emergency use against Covid-19 amid rising infections in the country.
Product Name : Paxlovid
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Molnupiravir is an investigational medicine developed by US based pharma firm Merc used to treat SARS-CoV-2 infection. In India, Merck Pharma Company had signed licensing agreements with various Indian pharma firms like Cipla, Dr Reddy’s, Emcure, Heter...
Product Name : Molnunat
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 30, 2021
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorization by local regulatory agencies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 27, 2021
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Merck & Co
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Hetero announced today that it has received the manufacturing and marketing approval for the investigational antiviral medicine ‘Remdesivir’ from the Drug Controller General of India (DCGI) for the treatment of Covid-19.
Product Name : Covifor
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2020
Lead Product(s) : Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable